JP2023541056A5 - - Google Patents
Info
- Publication number
- JP2023541056A5 JP2023541056A5 JP2023515802A JP2023515802A JP2023541056A5 JP 2023541056 A5 JP2023541056 A5 JP 2023541056A5 JP 2023515802 A JP2023515802 A JP 2023515802A JP 2023515802 A JP2023515802 A JP 2023515802A JP 2023541056 A5 JP2023541056 A5 JP 2023541056A5
- Authority
- JP
- Japan
- Prior art keywords
- eye
- insert according
- approximately
- delivery insert
- eye drop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078265P | 2020-09-14 | 2020-09-14 | |
| US63/078,265 | 2020-09-14 | ||
| US202163176430P | 2021-04-19 | 2021-04-19 | |
| US63/176,430 | 2021-04-19 | ||
| US202163190052P | 2021-05-18 | 2021-05-18 | |
| US63/190,052 | 2021-05-18 | ||
| PCT/US2021/050085 WO2022056392A1 (en) | 2020-09-14 | 2021-09-13 | Bioerodible ocular drug delivery insert and therapeutic method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541056A JP2023541056A (ja) | 2023-09-27 |
| JP2023541056A5 true JP2023541056A5 (cg-RX-API-DMAC7.html) | 2024-09-26 |
| JP7848190B2 JP7848190B2 (ja) | 2026-04-20 |
Family
ID=80629914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515802A Active JP7848190B2 (ja) | 2020-09-14 | 2021-09-13 | 生体侵食性眼薬送達挿入物及び治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12551368B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4696325A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7848190B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230067641A (cg-RX-API-DMAC7.html) |
| CN (2) | CN115243682A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021340733A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023004677A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3191463A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL301227A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002902A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022056392A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| AU2021340733A1 (en) * | 2020-09-14 | 2023-05-18 | EyePoint Pharmaceuticals, Inc. | Bioerodible ocular drug delivery insert and therapeutic method |
| WO2022251710A2 (en) | 2021-05-28 | 2022-12-01 | Sight Sciences, Inc. | Intraocular devices, systems, and methods |
| WO2023173093A1 (en) * | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | Continuous dosing regimen for treatment of a condition of the eye |
| CA3245207A1 (en) * | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | TREATMENT METHOD FOR MOISTURE-RELATED MACULAR DEGENERATION |
| KR20250002220A (ko) * | 2022-03-11 | 2025-01-07 | 아이포인트 파마슈티컬스, 인코포레이티드 | 안구 약물 전달 삽입물을 투여하여 연령 관련 황반 변성을 예방하는 방법 |
| WO2024020505A2 (en) * | 2022-07-22 | 2024-01-25 | SpyGlass Pharma, Inc. | Intraocular drug delivery systems and methods of use |
| JP2025523244A (ja) | 2022-07-22 | 2025-07-17 | スパイグラス ファーマ インコーポレイテッド | 眼内薬物送達システム及び使用方法 |
| CN119630398A (zh) * | 2022-08-16 | 2025-03-14 | 勃林格殷格翰国际有限公司 | 眼内用尼达尼布的药物制剂 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| ES3057289T3 (en) | 2023-04-27 | 2026-02-27 | Able Tx Ltd | Degradable elastomeric matrices, compositions comprising them, methods of preparing them and uses thereof |
| KR102618788B1 (ko) * | 2023-06-19 | 2023-12-28 | 국민대학교산학협력단 | 알티라티닙 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 안질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| KR20050108345A (ko) * | 2003-01-24 | 2005-11-16 | 컨트롤 딜리버리 시스템즈 인코포레이티드 | 탄산 탈수효소 저해제의 안구 전달을 위한 서방 장치와방법 |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| ES2565683T3 (es) | 2006-09-15 | 2016-04-06 | Xcovery, Inc. | Compuestos inhibidores de quinasa |
| NZ580126A (en) | 2007-04-05 | 2012-03-30 | Pfizer Prod Inc | Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2011079232A1 (en) | 2009-12-23 | 2011-06-30 | Psivida Us, Inc. | Sustained release delivery devices |
| JP5989780B2 (ja) * | 2011-09-14 | 2016-09-07 | フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． | 眼挿入装置および方法 |
| HK1202333A1 (en) | 2011-11-11 | 2015-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| WO2016176579A1 (en) | 2015-04-29 | 2016-11-03 | Psivida Us, Inc. | Injectable sustained release intraocular device |
| AU2016361579B2 (en) | 2015-11-25 | 2022-08-04 | Incept, Llc | Shape changing drug delivery devices and methods |
| PT109154B (pt) * | 2016-02-12 | 2019-11-05 | Univ De Coimbra | Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos |
| WO2018059556A1 (zh) | 2016-09-29 | 2018-04-05 | 贝达药业股份有限公司 | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 |
| AU2018226872A1 (en) * | 2017-03-03 | 2019-09-05 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
| EP4537830A3 (en) * | 2017-06-13 | 2025-06-11 | EyePoint Pharmaceuticals, Inc. | Bioerodible drug delivery devices |
| EP3781092A4 (en) * | 2018-04-19 | 2022-01-26 | Everads Therapy Ltd | DEVICE FOR INJECTING A SUBSTANCE INTO AN INTERLAYER OF A BODY TISSUE OR ORGAN |
| CN113301895B (zh) * | 2019-03-04 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 多靶点酪氨酸激酶抑制剂与egfr抑制剂联合在制备治疗肿瘤的药物中的用途 |
| AU2021340733A1 (en) * | 2020-09-14 | 2023-05-18 | EyePoint Pharmaceuticals, Inc. | Bioerodible ocular drug delivery insert and therapeutic method |
| WO2023173093A1 (en) * | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | Continuous dosing regimen for treatment of a condition of the eye |
-
2021
- 2021-09-13 AU AU2021340733A patent/AU2021340733A1/en active Pending
- 2021-09-13 CN CN202180019407.7A patent/CN115243682A/zh active Pending
- 2021-09-13 IL IL301227A patent/IL301227A/en unknown
- 2021-09-13 CA CA3191463A patent/CA3191463A1/en active Pending
- 2021-09-13 EP EP25211173.7A patent/EP4696325A3/en active Pending
- 2021-09-13 EP EP21867765.6A patent/EP4210682B1/en active Active
- 2021-09-13 MX MX2023002902A patent/MX2023002902A/es unknown
- 2021-09-13 BR BR112023004677A patent/BR112023004677A2/pt unknown
- 2021-09-13 KR KR1020237012132A patent/KR20230067641A/ko active Pending
- 2021-09-13 WO PCT/US2021/050085 patent/WO2022056392A1/en not_active Ceased
- 2021-09-13 JP JP2023515802A patent/JP7848190B2/ja active Active
- 2021-09-13 CN CN202211200614.5A patent/CN115531352B/zh active Active
-
2022
- 2022-02-14 US US17/671,060 patent/US12551368B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541056A5 (cg-RX-API-DMAC7.html) | ||
| JP6700348B2 (ja) | 持続型薬物送達インプラント | |
| CN115531352B (zh) | 可生物蚀解的眼部药物递送插入剂及治疗方法 | |
| JP6416154B2 (ja) | 眼房内ビマトプロスト注入物による眼圧低下 | |
| RU2018133133A (ru) | Способ лечения атрофической возрастной макулярной дегенерации | |
| JP2007535552A5 (cg-RX-API-DMAC7.html) | ||
| WO2003070219A1 (en) | Drug delivery system for the subconjunctival administration of fine grains | |
| de Smet | Corticosteroid intravitreal implants | |
| JP2025507154A5 (cg-RX-API-DMAC7.html) | ||
| KR20240156416A (ko) | 눈의 병태 치료를 위한 지속적 투여 요법 | |
| CN102781452B (zh) | 减少与皮质类固醇的眼内使用相关的眼压的发生率的方法 | |
| JP2025508127A5 (cg-RX-API-DMAC7.html) | ||
| JP2022527276A5 (cg-RX-API-DMAC7.html) | ||
| JP2003313119A (ja) | 微粒子結膜下投与ドラッグデリバリーシステム | |
| JP2022535223A (ja) | 眼疾患治療用組成物 | |
| TWI911436B (zh) | 生物可侵蝕之眼用藥物遞送插入物及治療方法 | |
| US20050192257A1 (en) | Predictors for patients at risk for glaucoma from steroid therapy | |
| Kiss et al. | Ocular implants–a novel approach in ocular drug delivery | |
| HK40118701A (zh) | 用於治疗眼睛病症的持续给药方案 | |
| HK40073855A (en) | Bioerodible ocular drug delivery insert and therapeutic method | |
| TW202345804A (zh) | 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法 | |
| WO2005082374A1 (en) | Predictors for patients at risk for glaucoma from steroid therapy | |
| HK1183436A (en) | Intraocular pressure reduction with intracameral bimatoprost implants | |
| HK1183436B (zh) | 用前房内比马前列素植入物的眼内压降低 | |
| NZ732418B2 (en) | Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions |